Tue, May 1, 2018
Mon, April 30, 2018
Fri, April 27, 2018

Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $113 on, Apr 30th, 2018

Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $112 to $113 on, Apr 30th, 2018.

Matthew has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $116 on, Friday, March 2nd, 2018
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $124 on, Friday, February 23rd, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $132 on, Friday, February 23rd, 2018
  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $125 on, Friday, February 23rd, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $102 on, Friday, February 23rd, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018